Market Place
Sourcing Support
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
11 Dec 2024 //
GLOBENEWSWIRE
Ocugen CEO to Present at NobleCon20 Emerging Growth Conf.
27 Nov 2024 //
GLOBENEWSWIRE
Ocugen Receives Orphan Drug Designation From EMA For OCU410ST
20 Nov 2024 //
GLOBENEWSWIRE
Ocugen Announces Data for OCU410 in Geographic Atrophy Treatment
19 Nov 2024 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Q3 2024 Financial Results
08 Nov 2024 //
GLOBENEWSWIRE
Ocugen Secures $30 Million in Debt Funding
07 Nov 2024 //
GLOBENEWSWIRE
Ocugen Showcases Retinal Gene Therapy Progress in NYC on Nov. 12
28 Oct 2024 //
GLOBENEWSWIRE
DSMB Approves Phase 2 Trial For Stargardt Disease
22 Oct 2024 //
GLOBENEWSWIRE
Ocugen To Host Call On November 8 For Q3 2024 Results
17 Oct 2024 //
GLOBENEWSWIRE
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
10 Oct 2024 //
GLOBENEWSWIRE
Ocugen Announces Removal Of Clinical Hold For OCU200 Trial
09 Oct 2024 //
GLOBENEWSWIRE
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
02 Oct 2024 //
GLOBENEWSWIRE
Ocugen to Join Fireside Chat at Chardan’s Genetic Medicines Conference
24 Sep 2024 //
GLOBENEWSWIRE
Ocugen CEO To Speak At U.S.-India Technology Workshop
09 Sep 2024 //
GLOBENEWSWIRE
Ocugen CSO To Participate In Gene Therapy Summit
05 Sep 2024 //
GLOBENEWSWIRE
Ocugen to Join Fireside Chat at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Ocugen Completes Dosing In Phase 1/2 Trial Of OCU410ST
28 Aug 2024 //
GLOBENEWSWIRE
Ocugen Announces Health Canada Approval for Phase 3 OCU400 Gene Therapy Trial
26 Aug 2024 //
GLOBENEWSWIRE
Ocugen Receives Health Canada Approval For OCU400 Phase 3 Trial
26 Aug 2024 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
08 Aug 2024 //
GLOBENEWSWIRE
Ocugen`s FDA Approval For Expanded Access In Retinitis Pigmentosa
05 Aug 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
02 Aug 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
31 Jul 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
31 Jul 2024 //
GLOBENEWSWIRE
Ocugen To Host Q2 2024 Results Call On August 8
29 Jul 2024 //
GLOBENEWSWIRE
Ocugen Completes Dosing In High-Dose Cohort Of OCU410 Trial
25 Jul 2024 //
GLOBENEWSWIRE
Ocugen Enrollment Approved for High Dose Cohort 3 in GARDian Study
21 Jun 2024 //
GLOBENEWSWIRE
Ocugen Doses First Patient In Phase 3 Trial Of OCU400 For Retinitis Pigmentosa
20 Jun 2024 //
GLOBENEWSWIRE
DSMB Approves OCU410 Geographic Atrophy Study Expansion
31 May 2024 //
GLOBENEWSWIRE
Ocugen to Present at BIO International Convention 2024
29 May 2024 //
GLOBENEWSWIRE
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
28 May 2024 //
GLOBENEWSWIRE
Ocugen CSO To Present On Modifier Gene Therapy At ISCT
20 May 2024 //
GLOBENEWSWIRE
Ocugen Completes Dosing For OCU410ST GARDian Stargardt Trial Cohort 2
15 May 2024 //
GLOBENEWSWIRE
Ocugen Provides Business Update with First Quarter 2024 Financial Results
14 May 2024 //
GLOBENEWSWIRE
Ocugen to Present at May 2024 Investor Conferences
10 May 2024 //
GLOBENEWSWIRE
Ocugen Distributing Series C Preferred To Common Holders
10 May 2024 //
GLOBENEWSWIRE
Ocugen To Host Q1 2024 Results, Business Updates Call On May 14
03 May 2024 //
GLOBENEWSWIRE
Ocugen To Present On Modifier Gene Therapy At Retina Congress
02 May 2024 //
GLOBENEWSWIRE
Ocugen to Present OCU400 "Modifier Gene Therapy" Ph1/2 Data at RCGT Summit
29 Apr 2024 //
GLOBENEWSWIRE
Ocugen to Present Modifier Gene Therapy Platform at ARVO 2024
26 Apr 2024 //
GLOBENEWSWIRE
Ocugen Completes Dosing Geographic Atrophy Cohort In OCU410 Trial
19 Apr 2024 //
GLOBENEWSWIRE
Ocugen At Noble Healthcare Virtual Conference
12 Apr 2024 //
GLOBENEWSWIRE
Ocugen Gets Positive Advice from EMA on OCU400 Gene Therapy
10 Apr 2024 //
GLOBENEWSWIRE
Ocugen Announces FDA Clearance of IND Amendment to Initiate OCU400 Ph 3 Trial
08 Apr 2024 //
GLOBENEWSWIRE
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
02 Apr 2024 //
GLOBENEWSWIRE
Ocugen to Host Conference Call to Provide Business & FY Updates
01 Apr 2024 //
GLOBENEWSWIRE
Ocugen Announces Positive Data of Medium Dose for OCU410ST for Stargardt Disease
01 Apr 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
18 Mar 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy
13 Mar 2024 //
GLOBENEWSWIRE
Ocugen to Present at Investing in Cures Summit
06 Mar 2024 //
GLOBENEWSWIRE
Ocugen Clinical Showcase Webcast Now Available
28 Feb 2024 //
GLOBENEWSWIRE
Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit
26 Feb 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Dosing Completion of Phase 1/2 Evaluating OCU410ST
22 Feb 2024 //
GLOBENEWSWIRE
Ocugen to Present at 2024 BIO CEO & Investor Conference
21 Feb 2024 //
GLOBENEWSWIRE
Ocugen to Host Clinical Showcase in New York City on February 21, 2024
14 Feb 2024 //
GLOBENEWSWIRE
Ocugen to Present at Pharma Market Research Conference
31 Jan 2024 //
GLOBENEWSWIRE
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
16 Jan 2024 //
GLOBENEWSWIRE
Ocugen Gains FDA Alignment on Aspects of OCU400 Phase 3 Study
21 Dec 2023 //
GLOBENEWSWIRE
Ocugen Announces OCU400 Receives RMAT Designation for Retinitis Pigmentosa
19 Dec 2023 //
GLOBENEWSWIRE
Ocugen Announces First Patient Dosed in Phase 1/2 Trial Evaluating OCU410
13 Dec 2023 //
GLOBENEWSWIRE
